Vitrolife AB (publ) Interim report Q2, 2022: Together for successful growth
VITROLIFE AB reported substantial growth in its Q2 and first half of 2022 financial results, with sales reaching SEK 829 million, a 117% year-on-year increase. Of this growth, 80% was attributed to acquisitions. Net income rose to SEK 130 million with earnings per share of SEK 0.96. The Americas saw remarkable sales growth of 241%.
However, EBITDA margin slightly decreased to 32.9% from 35.2% in Q2. For the first half, total sales reached SEK 1,581 million, with EBITDA margin also falling to 31.7%.
- Q2 sales up 117% to SEK 829 million.
- Net income increased to SEK 130 million.
- Significant sales growth in the Americas (241%).
- EBITDA per share rose by 63%.
- EBITDA margin declined to 32.9% from 35.2% in Q2.
- First half EBITDA margin decreased to 31.7% from 39.1%.
Insights
Analyzing...
GÖTEBORG, Sweden, July 15, 2022 /PRNewswire/ --
Second quarter
- Sales of SEK 829 (382) million, corresponding to an increase of
117% in SEK, whereof currency effect18% , acquired growth80% and organic growth18% . - Consumables increased sales by
24% in SEK, Technologies by37% in SEK, and Genetic Services contributed sales of SEK 341 million. - Strong growth in all market regions. Americas
241% , EMEA53% , Japan Pacific85% and Asia73% in local currencies. - Operating income before depreciation and amortisation (EBITDA) was SEK 273 (134) million, corresponding to a margin of
32.9% (35.2% ). EBITDA per share increased by63% . - Net income was SEK 130 (86) million, resulting in earnings per share of SEK 0.96 (0.79).
Pro forma
- Sales, adjusted for business related to Covid-19 tests, increased by
24% in SEK, and14% in local currencies. - EBITDA margin of
32.9% (32.8% ).
First half year
- Sales of SEK 1,581 (761) million, corresponding to an increase of
108% in SEK, whereof currency effect16% , acquired growth77% and organic growth15% . - Consumables increased sales by
25% in SEK, Technologies by18% in SEK, and Genetic Services contributed sales of SEK 645 million. - Strong growth in all market regions. Americas
247% , EMEA68% , Japan Pacific48% and Asia45% in local currencies. - Operating income before depreciation and amortisation (EBITDA) was SEK 501 (297) million, corresponding to a margin of
31.7% (39.1% ). EBITDA per share increased35% . - Net income was SEK 213 (205) million, resulting in earnings per share of SEK 1.56 (1.88).
Pro forma
- Sales, adjusted for business related to Covid-19 tests, increased by
21% in SEK, and12% in local currencies. - EBITDA margin of
31.7% (33.6% ).
Gothenburg, July 15, 2022
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, phone: +46 31 721 80 01
Patrik Tolf, CFO, phone: +46 31 766 90 21
This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on July 15, 2022.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Interim report Q2, 2022 |
View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ-interim-report-q2-2022-together-for-successful-growth-301587306.html
SOURCE Vitrolife AB (publ)
FAQ
What were VTRLY's Q2 2022 sales figures?
What is VTRLY's earnings per share for Q2 2022?
How did sales perform in the Americas for VTRLY in Q2 2022?
What was the EBITDA margin for VTRLY in Q2 2022?
What are VTRLY's total sales for the first half of 2022?
